April 10, 2026
Clinical Updates
Alyftrek® (vanzacaftor/tezacaftor/deutivacaftor) and Trikafta® (elexacaftor/tezacaftor/ivacaftor; ivacaftor) – Expanded indications
April 1, 2026 - Vertex announced the FDA approval of Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) tablets, for the treatment of cystic fibrosis (CF) in adult and pediatric patients aged 6 years and older who have a clinical diagnosis of CF and who have at least one variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein and for Trikafta (elexacaftor/tezacaftor/ivacaftor; ivacaftor) tablets and granules in patients 2 years and older.
Clinical Updates
Licart ® (diclofenac epolamine) – Expanded indication
March 27, 2026 - The FDA approved IBSA Pharma’s Licart (diclofenac epolamine), for the topical treatment of acute pain due to minor strains, sprains, and contusions in pediatric patients 6 years and older.
Clinical Updates
Neffy® (epinephrine) – Expanded indication
April 3, 2026, - ARS Pharmaceuticals announced the FDA approval of neffy (epinephrine) nasal spray, for emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 15 kg or greater.
New Generics
Lumigan® (bimatoprost) – First-time generic
April 1, 2026 - Lifestar Pharma launched an AB-rated generic version of AbbVie’s Lumigan (bimatoprost) 0.01% ophthalmic solution.
New Generics
Ofev® (nintedanib) – First-time generic
April 2, 2026 - Cipla launched an AB-rated generic version of Boehringer Ingelheim’s Ofev (nintedanib) capsules.